Patents by Inventor Roger Ryan Rothhaar

Roger Ryan Rothhaar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE
    Publication number: 20240059666
    Abstract: The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms made by these processes. The embodiments of the present invention further provide for the preparation of lasmiditan acetate, 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide acetate salt, and/or pharmaceutical compositions thereof, and/or uses of lasmiditan acetate and formulations thereof in subcutaneous drug delivery.
    Type: Application
    Filed: October 18, 2023
    Publication date: February 22, 2024
    Inventors: Aktham Aburub, David Andrew Coates, Scott Alan Frank, Mark Steven Kerr, Roger Ryan Rothhaar, Radhe Krishan Vaid
  • Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate
    Patent number: 11827618
    Abstract: The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms, such as tablets, made by these processes. Additionally, embodiments of the present invention provide tablets including 25 mg, 50 mg, 100 mg, or 200 mg free base equivalent of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate.
    Type: Grant
    Filed: April 14, 2023
    Date of Patent: November 28, 2023
    Inventors: Aktham Aburub, David Andrew Coates, Scott Alan Frank, Mark Steven Kerr, Roger Ryan Rothhaar, Radhe Krishan Vaid
  • PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
    Publication number: 20230322682
    Abstract: The present invention provides processes and key intermediates for the synthesis of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro-propane-2-yl)-1H-pyrazole-4-carboxamide:
    Type: Application
    Filed: September 9, 2021
    Publication date: October 12, 2023
    Inventors: Alonso Jose ARGUELLES DELGADO, Charles Todd EARY, Jared Wade FENNELL, Scott Alan FRANK, Nicholas Andrew MAGNUS, Elizabeth Ann MCFADDIN, Roger Ryan ROTHHAAR, Stacey Renee SPENCER, Radhe Krishan VAID
  • PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE
    Publication number: 20230250075
    Abstract: The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms made by these processes. The embodiments of the present invention further provide for the preparation of lasmiditan acetate, 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide acetate salt, and/or pharmaceutical compositions thereof, and/or uses of lasmiditan acetate and formulations thereof in subcutaneous drug delivery.
    Type: Application
    Filed: April 14, 2023
    Publication date: August 10, 2023
    Inventors: Aktham Aburub, David Andrew Coates, Scott Alan Frank, Mark Steven Kerr, Roger Ryan Rothhaar, Radhe Krishan Vaid
  • PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE
    Publication number: 20230250076
    Abstract: The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms made by these processes. The embodiments of the present invention further provide for the preparation of lasmiditan acetate, 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide acetate salt, and/or pharmaceutical compositions thereof, and/or uses of lasmiditan acetate and formulations thereof in subcutaneous drug delivery.
    Type: Application
    Filed: April 14, 2023
    Publication date: August 10, 2023
    Inventors: Aktham Aburub, David Andrew Coates, Scott Alan Frank, Mark Steven Kerr, Roger Ryan Rothhaar, Radhe Krishan Vaid
  • PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE
    Publication number: 20230137090
    Abstract: The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-tri-fluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms made by these processes. The embodiments of the present invention further provide for the preparation of lasmiditan acetate, 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide acetate salt, and/or pharmaceutical compositions thereof, and/or uses of lasmiditan acetate and formulations thereof in subcutaneous drug delivery.
    Type: Application
    Filed: July 6, 2020
    Publication date: May 4, 2023
    Inventors: Aktham Aburub, David Andrew Coates, Scott Alan Frank, Mark Steven Kerr, Roger Ryan Rothhaar, Radhe Krishan Vaid
  • 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HTreceptor agonist
    Patent number: 8580780
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —S—R14; and other substituents are as defined in the specification.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: November 12, 2013
    Assignee: Eli Lilly and Company
    Inventors: John Gordon Allen, Karin Briner, Christopher Stanley Galka, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothhaar, Michael Wade Tidwell, Frantz Victor, Deyi Zhang, Steven Armen Boyd, Arundhati S. Deo, Wai-Man Lee, Christopher Stephen Siedem, Ajay Singh
  • 6-substituted-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HTreceptor agonists
    Patent number: 8420631
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where R6 is —C?C—R10, —CH?CR11R11?, or —(C0-C8)alkyl-Ar2 optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents and other substituents are as defined in the specification.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: April 16, 2013
    Assignee: Eli Lilly and Company
    Inventors: John Gordon Allen, Karin Briner, Anne Marie Camp, Manuel Javier Cases-Thomas, Richard Charles Hoying, Maria Angeles Martinez-Grau, Michael Philip Mazanetz, Natalia Pokrovskaia, Richard Edmund Rathmell, Roger Ryan Rothhaar, Selma Sapmaz, Andrew Caerwyn Williams
  • 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist
    Publication number: 20120028961
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —S—R14; and other substituents are as defined in the specification.
    Type: Application
    Filed: July 28, 2011
    Publication date: February 2, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: JOHN GORDON ALLEN, Karin Briner, Michael Philip Cohen, Christopher Stanley Galka, Sarah Lynne Hellman, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothhaar, Michael Wade Tidwell, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang, Steven Armen Boyd, Richard Gerard Conway, Arundhati S. Deo, Wai-Man Lee, Christopher Stephen Siedem, Ajay Singh, Michael Philip MAZANETZ
  • 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HTreceptor agonists
    Patent number: 8022062
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —C?C—R10, —O—R12, —S—R14, or —NR24R25; and other substituents are as defined in the specification.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: September 20, 2011
    Assignee: Eli Lilly and Company
    Inventors: John Gordon Allen, Karin Briner, Michael Philip Cohen, Christopher Stanley Galka, Sarah Lynne Hellman, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothhaar, Michael Wade Tidwell, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang, Michael Philip Mazanetz
  • 6-N-linked heterocycle-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HTreceptor agonists
    Patent number: 7981882
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: July 19, 2011
    Assignee: Eli Lilly and Company
    Inventors: Karin Briner, Anne Marie Camp, Alan Cornell, Michael Philip Mazanetz, Roger Ryan Rothhaar, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang
  • 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists
    Publication number: 20080214520
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.
    Type: Application
    Filed: September 1, 2006
    Publication date: September 4, 2008
    Inventors: Karin Briner, Anne Marie Camp, Alan Cornell, Michael Philip Mazanetz, Roger Ryan Rothhaar, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang
  • 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists
    Publication number: 20080207897
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where R6 is —C?C—R10, —CH?CR11R11?, or —(C0-C8)alkyl-Ar2 optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents and other substituents are as defined in the specification.
    Type: Application
    Filed: September 1, 2006
    Publication date: August 28, 2008
    Inventors: John Gordon Allen, Karin Briner, Anne Marie Camp, Manuel Javier Cases-Thomas, Richard Charles Hoying, Maria Angeles Martinez-Grau, Michael Philip Mazanetz, Natalia Pokrovskaia, Richard Edmund Rathmell, Roger Ryan Rothhaar, Selma Sapmaz, Andrew Caerwyn Williams
  • Piperazine- and piperidine-derivatives as melanocortin receptor agonists
    Patent number: 7186715
    Abstract: The present invention relates to melanocortin receptor agonists of formula I, which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction
    Type: Grant
    Filed: January 23, 2002
    Date of Patent: March 6, 2007
    Assignee: Eli Lilly and Company
    Inventors: Karin Briner, Christopher William Doecke, Vincent Mancuso, Michael John Martinelli, Timothy Ivo Richardson, Roger Ryan Rothhaar, Qing Shi, Chaoyu Xie
  • Serotonergic benzofurans
    Patent number: 6881733
    Abstract: The present invention provides serotonergic benzofurans of Formula (I): where A, R, R1, R2, R3, and R4 are as described in the specification.
    Type: Grant
    Filed: July 21, 2000
    Date of Patent: April 19, 2005
    Assignee: Eli Lilly and Company
    Inventors: Karin Briner, Joseph Paul Burkhart, Timothy Paul Burkholder, Brian Eugene Cunningham, Matthew Joseph Fisher, William Harlan Gritton, Cynthia Darshini Jesudason, Shawn Christopher Miller, Jeffrey Thomas Mullaney, Matthew Robert Reinhard, Roger Ryan Rothhaar, Freddie Craig Stevens, Leonard Larry Winneroski, Yanping Xu, Yao-Chang Xu
  • Piperazine- and piperidine-derivatives as melanocortin receptor agonists
    Publication number: 20040082590
    Abstract: The present invention relates to melanocortin receptor agonists of formula I, which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction.
    Type: Application
    Filed: July 11, 2003
    Publication date: April 29, 2004
    Inventors: Karin Briner, Christopher William Doecke, Vincent Mancuso, Michael John Martinelli, Timothy Ivo Richardson, Roger Ryan Rothhaar, Qing Shi, Chaoyu Xie